Consolidative Use of Radiotherapy to Block Oligoprogression in Patients With Metastatic Melanoma
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Stereotactic Body Radiation Therapy (SBRT).
- Who it may be relevant to
- Registry conditions: Metastatic Melanoma, OligoProgressive Metastatic Disease. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Canada
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Consolidative Use of Radiotherapy to Block Oligoprogression in Patients With Metastatic Melanoma (CURB-Melanoma) - a Phase 2 Clinical Trial
Overview
This open-label, prospective, single-arm Phase II trial explores whether adding stereotactic body radiotherapy (SBRT) or hypofractionated radiotherapy to oligoprogressive lesions can help delay disease progression in patients with metastatic melanoma. Participants may have up to ten extracranial oligoprogressive sites, with no upper limit on the total number of metastatic lesions. The study aims to assess whether targeting these progressing sites with focused radiotherapy can extend progression-free survival in this patient population.
Detailed description
This study evaluates the use of stereotactic body radiotherapy (SBRT) or hypofractionated radiotherapy in patients with metastatic melanoma who have up to 10 extracranial oligoprogressive lesions while receiving first-line systemic therapy. Oligoprogression refers to progression at a limited number of sites, while the remaining disease remains controlled by systemic treatment.
Participants will continue their current systemic therapy and receive SBRT or hypofractionated radiotherapy to all oligoprogressive lesions. The study will assess whether this approach can delay overall disease progression and extend the duration of benefit from ongoing systemic therapy.
Imaging will be used to monitor disease progression, and blood samples will be collected at baseline, after radiation, and at disease progression for exploratory analysis. Additional outcomes include overall survival, time on current therapy, toxicity, quality of life, and out-of-field response.
Interventions
- Radiation Stereotactic Body Radiation Therapy (SBRT)
SBRT will be delivered as per institutional standard.
Primary outcome measures
- Progression-Free Survival (PFS) assessed by radiological imaging using RECIST v1.1 criteria [Time frame: From enrollment up to 24 months]
Secondary outcome measures (6)
- Overall Survival (OS) measured from date of enrollment to death from any cause [Time frame: Enrollment up to 24 months]
- Time on Current Systemic Therapy After Initial Oligoprogression [Time frame: From enrollment up to 24 months]
- Out-of-field response assessed by radiological imaging (CT, PET-CT, or MRI) [Time frame: From enrollment up to 24 months.]
- Reporting acute and late toxicities of SBRT [Time frame: Enrollment up to 24 months]
- Participant-reported adverse events measured using PRO-CTCAE questionnaire [Time frame: From baseline through follow-up (up to 24 months)]
- Participant-reported quality of life measured using EORTC QLQ-C30 questionnaire [Time frame: From baseline through follow-up (up to 24 months)]
Eligibility criteria
Inclusion criteria
- Age 18 or older
- ECOG 0-2
- Willing and able to provide informed consent
- Metastatic melanoma detected on imaging and clinically confirmed.
- Treated with first line immunotherapy or BRAF inhibitors.
- No upper limit to the number of total metastatic sites, but a maximum of ten progressive metastatic sites, inclusive of primary disease and metastatic lesions, all of which must be extra cranial.
- Patients who had any prior radiation therapy near or overlapping with the oligoprogressive sites are allowed to enroll.
- All sites of oligoprogression that can be safely treated with SBRT or hypofractionated radiotherapy.
Exclusion criteria
- >10 extracranial sites of progressive disease.
- Pregnancy.
- Leptomeningeal disease.
- Serious medical comorbidities precluding radiotherapy, such as ataxia-telangiectasia or scleroderma.
- Prior radiotherapy near the oligoprogressive lesion precluding SBRT or hypofractionated radiotherapy due to exceeding OAR tolerance.
- Any psychological, sociological or geographical issue potentially hampering compliance with the study.
- Any other condition which in the judgment of the investigator would make the patient inappropriate for entry into this study.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- N/A
- Model
- Single group
- Masking
- Open label
- Primary purpose
- Treatment
Study locations
Canada · 1 center
- University Health Network — Toronto
Publications
- Icht O, Sun A, Wong P, McPartlin A, Muniz TP, Spreafico A, Saibil SD, Lukens JN, Karam SD, De Almeida J, Butler MO, Tsai CJ. Consolidative use of radiotherapy to block oligoprogression in patients with metastatic melanoma on Systemic Therapy (CURB-Melanoma) - a single arm, phase 2 clinical trial. Front Oncol. 2026 Jul 6;16:1841070. doi: 10.3389/fonc.2026.1841070. eCollection 2026. PMID 42518820
Identifiers
NCT: NCT07112170 · 25-5162